MedTrace Logo

The Effects of BAY1193397 on Skin Capillary Blood Flow and Transcutaneous Oxygen Pressure

NCT03128320 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 23

Last updated 2020-08-13

No results posted yet for this study

Summary

The purpose of the study is to analyse skin blood flow in diabetic patients. The patients receive a single dose of placebo, 1 mg BAY1193397, and 5 mg BAY1193397. The analysis of safety and tolerability are secondary objectives of this study.

Conditions

  • Diabetic Foot

Interventions

DRUG

BAY1193397

Single dose of 1 mg BAY1193397 given in the fasted state

DRUG

BAY1193397

Single dose of 5 mg BAY1193397 given in the fasted state

DRUG

Placebo

Single dose of placebo given in the fasted state

Sponsors & Collaborators

Principal Investigators

  • Bayer Study Director · Bayer

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
55 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-05-25
Primary Completion
2019-09-06
Completion
2019-10-28

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03128320 on ClinicalTrials.gov